Form 4: Syndax Pharmaceuticals Director Legault Pierre Reports Stock Award and Holdings
SEC Form 4
Director Pierre Legault reports the acquisition of 25,000 shares of Syndax Pharmaceuticals stock and the disposal of 90,000 shares.
Summary
- On February 5, 2025, Pierre Legault, a director of Syndax Pharmaceuticals Inc., reported a transaction involving the company's common stock.
- Legault acquired 25,000 shares of common stock through an award.
- Legault disposed of 90,000 shares of common stock.
- Following the reported transactions, Legault beneficially owns 90,000 shares of Syndax Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the stock transactions of a company director.
- The transactions may influence investor perception of the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of stock acquisition and disposal. |
| 02/07/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.